ArticleScientific reports2025
Oxindole based sulfonyl derivatives synthesized as potent inhibitors of alpha amylase and alpha glucosidase along with their molecular docking study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus, a persistent metabolic disorder, impedes the proper metabolism of proteins, carbohydrates, and lipids, leading to various physiological complications. A spectrum of synthetic alpha-glucosidase inhibitors is employed to mitigate glucose levels; however, prolonged use of these medications has been associated with a range of adverse effects. The current study particularly focuses on piperidin-indolin based sulfonyl derivatives, a class of heterocyclic compounds to assess the inhibitory efficacy of these synthesized compounds against α-amylase and α-glucosidase enzymes. All compounds showed excellent inhibitory activity in the range between 1.90 ± 0.10 to 16.80 ± 0.30 µM (amylase) and 1.20 ± 0.01 to 15.40 ± 0.30 µM (glucosidase). Limited structural activity relationship has been established for all compounds which suggest compound 16 has many folds better potential then standard drug. Molecular docking revealed that the most active compounds established stable hydrogen-bonding and hydrophobic interactions within the catalytic pockets of α-amylase and α-glucosidase, consistent with key active-site residues known to mediate inhibition. Molecular dynamics simulations further confirmed the stability of the ligand-enzyme complexes, particularly the α-glucosidase-compound 7 system, which maintained a Cα RMSD range of 1.5-2.2 Å throughout 200 ns. Binding free energy calculations using MM-GBSA yielded an average ΔG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.